Update shared on06 Sep 2025
With both consensus revenue growth and net profit margin forecasts for Metropolis Healthcare remaining stable, analysts have left their fair value estimate unchanged at ₹2145.
What's in the News
- Board meeting scheduled to consider and approve un-audited standalone and consolidated financial results for the quarter ended June 30, 2025, and to discuss other matters.
Valuation Changes
Summary of Valuation Changes for Metropolis Healthcare
- The Consensus Analyst Price Target remained effectively unchanged, at ₹2145.
- The Consensus Revenue Growth forecasts for Metropolis Healthcare remained effectively unchanged, at 15.8% per annum.
- The Net Profit Margin for Metropolis Healthcare remained effectively unchanged, at 15.29%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.